Link Search Menu Expand Document

Link to CT1.v1 IPD and interactive site

Note: please expect a short (30 second) delay while the site loads

Imputed IPD from ~150 trial publications in breast, colorectal, lung, and prostate cancer, which in aggregate comprise ~220,000 overall survival OS) or event-free survival events (e.g. progression free survival, PFS).

Citations: “Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects” by Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger. Nat Commun 13, 873 (2022).

Plana, D., Fell, G., Alexander, B. M., Palmer, A. C. & Sorger, P. K. Imputed individual participant data from oncology clinical trials. Synpase repository. (2021).

Link to CT2.v1 IPD

Donwload zip file with imputed IPD here

Imputed IPD from combination therapies with immune-checkpoint inhibitors across six cancer types including breast, gastric, head and neck, lung, melanoma, and renal.

Citation: “Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors” by Adam C. Palmer, Benjamin Izar , Haeun Hwangbo and Peter K. Sorger. Clin Cancer Res (2022) 28 (2): 368–377.